跳至主要内容
临床试验/CTRI/2024/02/062580
CTRI/2024/02/062580招募中3 期

A randomized double-blind placebo controlled clinical study for the comparative evaluation of efficacy and tolerability of proteoglycan in improving knee joint health in adult subjects with mild osteoarthritis - NI

Daehan Chemtech Co Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Ambulatory, male and female subjects 40-75 years of age.
  • 2.KL (Kellgren-Lawrence) grade of 1 to 2.
  • 3.At least 30 on 100 mm visual analogue scale.
  • 4.Subjects having mild-to-moderate pain in knee joint upon completion of 30-second Chair Stand Test or 80-meter Fast-Paced Walk Test, and otherwise no knee pain at rest.
  • 5.Subjects willing to refrain from taking ibuprofen, aspirin or other NSAIDs or any other pain reliever (OTC or prescription) during the entire trial.
  • 6.Subjects willing to sign the informed consent and comply with study procedure.
  • 7.Subjects able to complete 20-meter walk test.

排除标准

  • 1. Subjects with any possible signs / indication / history of arthritis,
  • joint disorders including dislocations and quadriceps tendons tear.
  • 2. Subjects with history of underlying inflammatory arthropathy or
  • severe RA or OA.
  • 3.Subjects having used any immunosuppressive drugs in the last 6
  • months (including steroids or biologics) and those with history of
  • immune system and autoimmune disorders.
  • 4.Subjects with a history of knee or hip joint replacement surgery, or
  • any hip or back pain which interferes with ambulation.
  • 5.Subjects with BMI less than 18.5 or more than 30.
  • 6.Subjects who consumed the medicines or supplements related
  • with joint health within 30 days before screening visit.
  • 7.Subjects who are not acceptable for the test by the judgment of PI.
  • 8.Subjects with the history of tobacco smoking.
  • 9.Subjects expecting the surgery during the study duration period.
  • 10.Female subjects, who are pregnant, breast feeding or planning to
  • become pregnant.
  • 11.Subjects having known allergy to non-steroidal anti-inflammatory
  • drugs (NSAIDs) (including aspirin) or has a suspected
  • hypersensitivity, allergy or sensitivity to herbal products.
  • 12.Subjects who have any physical disability which could interfere
  • with their ability to perform the functional performance measures
  • included in this protocol.
  • 13.Subjects with history of gout.
  • 14.Subjects who have received any corticosteroids, NSAIDs,
  • glucosamine, and or chondroitin, within the past 90 days prior to the
  • screening visit or any form of intra-articular treatment / injections with
  • corticosteroids or hyaluronic acid within 90 days preceding the
  • screening visit.
  • 15.Subjects with the history of congestive heart failure or any
  • vascular conditions.
  • 16.Subjects with the evidence or history of clinically significant (in the
  • judgment of the Investigator) hematological, renal, endocrine,
  • pulmonary, gastrointestinal, cardiovascular, hepatic or neurologic
  • diseases, or malignancies, hypothyroidism.
  • 17.Subjects with history of systemic lupus erythematous (SLE).
  • 18.Subjects with history of high alcohol intake (greeter than 2
  • standard drinks per day).
  • 19.Subjects with history of any psychiatric disorders that may impair
  • the ability of subjects to provide written informed consent.
  • 20.Subjects who have participated in any other trials involving
  • investigational or marketed products within 90 days prior to the
  • screening visit.
  • 21.Subjects who are currently or within 30 days prior to the screening visit on prescription or OTC medications / pain relievers
  • such as acetaminophen / paracetamol, ibuprofen, aspirin or other
  • NSAIDs or any natural health product, (excluding vitamins).

研究者

发起方
Daehan Chemtech Co Ltd

相似试验

Clinical study on knee joint health in adult subjects | 临床试验